Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives

Table 3

Inhibitory effects of some NS3 helicase inhibitors.

NS3 helicase inhibitor	IC50 (μM)			References
	Helicase
	DNA	RNA	ATPase
DRBT	1.5	>500	No inhibition	[49]
TBBT	20	60	No inhibition	[49]
Soluble blue HT	40	Inhibition	23.8	[51]
Ring-expanded (fat) nucleoside analogues	7–11	5.5–12	Activation	[52]
AICAR analogue (compound 4)	37	No inhibition	ND	[53]
QU663	𝐾𝑖, 0.75	ND	No inhibition	[54]
p14	0.2	ND	No inhibition	[55]
DBMTr	17.6	No inhibition	No inhibition	[56, 57]
Acridone derivatives	1.5–20	ND	No inhibition	[58, 59]
Thiazolpiperazinyl derivative (compound 23)	110	ND	>1000	[60]
(BIP)2B	5.4	0.7	Inhibition (in the presence of RNA)	[61]
Tropolone derivatives	3.4–17.8	ND	ND	[62]
Tetrahydroacridine derivative, 3a	𝐾𝑖, 0.02	ND	ND	[63]
Manoalide	ND	15	70	[64]
Thioflavin S	10	12	ND	[65]
SG1-23-1	ND	11.7 μg/mL	No inhibition	[66]
LOPAC compounds	0.6–3.7	0.8–8.9	ND	[67]
C-29EA	ND	18.9 μg/mL	No inhibition	[68]
Psammaplin A	ND	17	32	[69]
Cholesterol sulfate	ND	1.7	No inhibition	[70]

ND: not determined.